UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000063708
Receipt number R000072807
Scientific Title Study Evaluating the Effects of a Test Food on Sleep --A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Comparative Trial--
Date of disclosure of the study information 2026/11/20
Last modified on 2026/11/17 17:39:33

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study Evaluating the Effects of a Test Food on Sleep
--A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Comparative Trial--

Acronym

Study Evaluating the Effects of a Test Food on Sleep

Scientific Title

Study Evaluating the Effects of a Test Food on Sleep
--A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Comparative Trial--

Scientific Title:Acronym

Study Evaluating the Effects of a Test Food on Sleep

Region

Japan


Condition

Condition

No

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The purpose of this study is to evaluate the effects of short-term consumption of the test food on subjective sleep status and daytime functioning.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

OSA Sleep Inventory (MA Version)

Key secondary outcomes

Japanese Version of the Epworth Sleepiness Scale (JESS)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Oral intake of the test food (2 tablets per day for 11 days)

Interventions/Control_2

Oral intake of the placebo food (2 tablets per day for 11 days)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

60 years-old >

Gender

Male and Female

Key inclusion criteria

This study is open to individuals who meet all of the following criteria:
1) Men and women aged 20 or older but under 60 at the time of obtaining consent to participate in the study.
2) Healthy individuals with no chronic medical conditions.
3) Individuals who are dissatisfied with the quality of their sleep (e.g., reduced daytime performance, severe daytime sleepiness, difficulty falling asleep, shallow sleep, difficulty waking up, etc.) .
4) Individuals whose work schedule generally consists of daytime shifts five days a week, with Saturdays and Sundays as days off.
5) Individuals who have received a thorough explanation of the purpose and content of this trial, have understood it, and have consented in writing to participate in the trial of their own free will.
6) Individuals who are able to visit the facility on the designated examination date and undergo the prescribed examinations.
7) Individuals whom the principal investigator deems appropriate to participate in this trial.

Key exclusion criteria

Any individual who meets any of the following criteria will be excluded from this study.
Individuals
1) w with chronic diseases or undergoing treatment for any illness.
2) with suspected SAS or current or past treatment for SAS.
3) with suspected or confirmed nocturia, benign prostatic hyperplasia, or overactive bladder.
4) with current or past chronic fatigue syndrome, mental or sleep disorders, hypertension, diabetes, dyslipidemia, or other serious diseases.
5) with current or past serious liver, kidney, heart, lung, blood, or digestive diseases.
6) with severe anemia.
7) regularly using oral or topical medications for illness within the past month.
8) with a BMI of 30.0 kg/m2 or higher.
9) at risk of allergies to test food ingredients, other foods, or drugs.
10) regularly using sleep-related health foods or supplements now or in the past 3 months, or planning to use them during the study.
11) regularly using supplements or probiotics mainly containing lactic acid bacteria or bifidobacteria.
12) who regularly consume alcohol.
13) who regularly consume 400 mg or more of caffeine per day.
14) with irregular bedtimes or wake-up times, or routinely sleeping less than 4 hours after going to bed at or after midnight.
15) unable to sleep alone or whose sleep may be disturbed by children, pets, etc.
16) at risk of dermatitis from EEG electrode pads, including those with adhesive-related dermatitis history.
17) planning changes in daily routines or sleeping environments due to travel or other reasons during the study.
18) currently in another clinical trial or within 3 months of its completion.
19) who are pregnant, breastfeeding, may be pregnant, or intend to become pregnant during the trial period.
20) Any other individuals whom the principal investigator deems ineligible for this trial.

Target sample size

70


Research contact person

Name of lead principal investigator

1st name Tatsuhiko
Middle name
Last name Hirota

Organization

Asahi Quality & Innovations, Ltd.

Division name

Core Technology Research Institute

Zip code

302-0106

Address

1-21,Midori 1-chome,Moriya-shi,Ibaraki,302-0106

TEL

0297-46-1111

Email

tatsuhiko.hirota@asahi-qi.co.jp


Public contact

Name of contact person

1st name Ryoma
Middle name
Last name Shimizu

Organization

TES Holdings Co., Ltd.

Division name

Administrative Department of Clinical Trials

Zip code

110-0015

Address

6F Kairaku Building 2-7-5 Higashiueno Taito-ku Tokyo 110-0015, JAPAN

TEL

+81-3-6801-8480

Homepage URL


Email

r.shimizu@tes-h.co.jp


Sponsor or person

Institute

TES Holdings Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Asahi Quality & Innovations, Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ueno-Asagao Clinic Ethical Review Committee

Address

6F Kairaku Building 2-7-5 Higashiueno Taito-ku Tokyo 110-0015, JAPAN

Tel

+81-3-6240-1162

Email

jimukyoku@tes-h.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2026 Year 11 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2026 Year 11 Month 11 Day

Date of IRB

2026 Year 11 Month 12 Day

Anticipated trial start date

2026 Year 12 Month 01 Day

Last follow-up date

2026 Year 12 Month 26 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2026 Year 11 Month 20 Day

Last modified on

2026 Year 11 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072807